Vabomere, Vaborem(vaborbactam)
Vabomere, Vaborem (vaborbactam) is a small molecule pharmaceutical. Vaborbactam was first approved as Vabomere on 2017-08-29. It is used to treat bacterial infections in the USA. It has been approved in Europe to treat bacteremia, bacterial infections, pneumonia, respiratory tract infections, and urinary tract infections amongst others.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| respiratory tract diseases | D012140 |
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Combinations
Vabomere
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Meropenem
+
Vaborbactam
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VABOMERE | REMPEX | N-209776 RX | 2017-08-29 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vabomere | New Drug Application | 2020-11-23 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MEROPENEM / VABORBACTAM, VABOMERE, REMPEX | |||
| 2027-08-29 | GAIN | ||
| 2022-08-29 | NCE | ||
HCPCS
Code | Description |
|---|---|
| J2186 | Injection, meropenem and vaborbactam, 10mg/10mg (20mg) |
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | 2 | — | — | 2 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | 2 | — | — | 2 |
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | — | 2 | — | — | 2 |
| Iatrogenic disease | D007049 | — | — | 1 | — | — | 1 | ||
| Healthcare-associated pneumonia | D000077299 | — | — | 1 | — | — | 1 | ||
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | — | 1 | — | — | 1 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VABORBACTAM |
| INN | vaborbactam |
| Description | Vaborbactam (INN) is a non-β-lactam β-lactamase inhibitor discovered by Rempex Pharmaceuticals, a subsidiary of The Medicines Company. While not effective as an antibiotic by itself, it restores potency to existing antibiotics by inhibiting the β-lactamase enzymes that would otherwise degrade them. When combined with an appropriate antibiotic it can be used for the treatment of gram-negative bacterial infections.
|
| Classification | Small molecule |
| Drug class | beta-lactamase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)C[C@@H]1CC[C@H](NC(=O)Cc2cccs2)B(O)O1 |
Identifiers
| PDB | — |
| CAS-ID | 1360457-46-0 |
| RxCUI | 1945213 |
| ChEMBL ID | CHEMBL3317857 |
| ChEBI ID | — |
| PubChem CID | 56649692 |
| DrugBank | DB12107 |
| UNII ID | 1C75676F8V (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,494 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,651 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more